Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data CytoMed Therapeutics Ltd files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2023
FY2024
FY2025
Revenue
0.05
0.25
Research and development
1.14
1.2
1.4
1.72
Interest expense
0.09
0.04
0.01
0.02
Pre-tax income
-2.33
-3.13
-1.85
-3.11
Income tax
0
0
Net income to minority interests
-0
-0
-0
Net income
-2.34
-3.13
-1.84
-3.1
EPS, basic
-0.29
-0.16
-0.27
EPS, diluted
-0.30
-0.29
-0.16
-0.27
Balance sheet
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
1.2
4.56
3.65
1.63
Receivables
0.68
0.83
0.75
1.22
Total current assets
1.86
7.65
4.39
2.85
Property, plant and equipment
1.85
1.57
2.38
2.87
Intangible assets
0.01
0.01
0.07
0.1
Total assets
3.9
9.38
7.37
6.21
Accounts payable
0.31
0.4
0.32
0.35
Short-term debt
0.25
0.03
0.03
0.03
Total current liabilities
3.11
0.54
0.44
0.55
Lease liabilities
0.01
0.02
0.04
Total liabilities
3.46
0.85
0.75
0.88
Retained earnings
-6.12
-9.35
-10.9
-14.6
Shareholders' equity
0.44
8.52
6.56
5.09
Minority interests
-0
-0
0.06
0.24
Total equity
0.44
8.52
6.62
5.33
Total liabilities and equity
3.9
9.38
7.37
6.21
Cash flow statement
FY2022
FY2023
FY2024
FY2025
Net income
-2.34
-3.13
-1.85
-3.11
Cash from operations
-1.04
-2.6
-1.98
-2.88
Capital expenditures
-0.35
-0.04
-1.02
-0.5
Cash from investing
-0.35
-2.14
0.82
0.72
Debt repaid
-0.05
-0.03
-0.03
-0.03
Cash from financing
0.72
8.28
-0.05
0.16
Exchange rate effect
-0.02
-0.01
0.09
-0.03
Free cash flow
-1.4
-2.65
-3.01
-3.37
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $0.84 on November 11, 2026.
Profitability
Metric
Value
How it is calculated
Pre-tax margin
-1,232.0%
Pre-tax income / revenue.
Net margin
-1,227.0%
Net income / revenue.
FCF margin
-1,336.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-1,140.0%
Cash from operations / revenue.
Return on equity (ROE)
-53.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-45.6%
Net income / average total assets.
R&D / revenue
683.6%
Research and development expense / revenue.
Capex / revenue
196.6%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
395.9%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-22.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
126.5%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-15.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
16.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.17x
Current assets / current liabilities.
Quick ratio
5.17x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.95x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.27
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$9.9M
Share price x shares outstanding.
Enterprise value
$8.3M
Market cap + total debt - cash - short-term investments.
P/S
39.4x
Market cap / revenue.
P/B
1.95x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.99x
Market cap / tangible book value, when positive.
EV/Sales
32.9x
Enterprise value / revenue.
FCF yield
-33.9%
Free cash flow / market cap.
Earnings yield
-31.2%
Net income / market cap (the inverse of P/E).
What was CytoMed Therapeutics Ltd's revenue in fiscal 2025?
CytoMed Therapeutics Ltd reported revenue of $252.3K for fiscal 2025, 395.9% higher than the year before.
Was CytoMed Therapeutics Ltd profitable in fiscal 2025?
No. It reported a net loss of $3.1M.
How much free cash flow did CytoMed Therapeutics Ltd generate in fiscal 2025?
Cash from operations of $2.9M minus capital expenditures of $496.0K left free cash flow of -$3.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.